CME Group (NASDAQ:CME) Announces Earnings Results

CME Group (NASDAQ:CME) released its earnings results on Wednesday. The financial services provider reported $3.36 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.25, FiscalAI reports. The company had revenue of $1.88 billion for the quarter, compared to analysts’ expectations of $1.77 billion. CME Group had a return on equity of 14.65% and a net margin of 62.45%.The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.80 EPS.

CME Group Stock Performance

CME Group stock traded down $4.20 during midday trading on Wednesday, reaching $280.20. The stock had a trading volume of 494,545 shares, compared to its average volume of 2,271,167. CME Group has a 12 month low of $251.90 and a 12 month high of $329.16. The firm’s 50-day moving average price is $305.53 and its 200 day moving average price is $285.92. The firm has a market capitalization of $100.49 billion, a PE ratio of 25.06, a P/E/G ratio of 2.94 and a beta of 0.26. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.12.

CME Group Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Tuesday, March 10th were paid a $1.30 dividend. The ex-dividend date was Tuesday, March 10th. This represents a $5.20 dividend on an annualized basis and a yield of 1.9%. This is an increase from CME Group’s previous quarterly dividend of $1.25. CME Group’s dividend payout ratio (DPR) is presently 46.59%.

More CME Group News

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Record top-line and volumes — CME reported its highest quarterly revenue and record daily trading activity, which drove operating income and adjusted EPS higher year-over-year. CME Group Inc. Reports Record Revenue, Adjusted Operating Income, Adjusted Net Income and Adjusted Earnings Per Share for Q1 2026
• Positive Sentiment: Historic volumes — daily contracts surged (~36.2M, +22%), underscoring that volatility-driven flow remains a revenue driver for the exchanges. Strong volume is a durable earnings lever if sustained. CME Group (CME) Stock Slides Following Record-Breaking Q1 2026 Performance
• Neutral Sentiment: Mixed analyst picture — Wall Street price targets remain mostly above current levels (median targets in the low $300s), reflecting confidence in structural margins even as estimates differ. Watch guidance and next?quarter volume assumptions. CME GROUP ($CME) Releases Q1 2026 Earnings
• Negative Sentiment: Misses vs some estimates — several outlets flagged that EPS and/or revenue came in slightly below particular consensus figures (headline callers described a “double miss”), which pressured the stock despite strong underlying metrics. CME Stock Under Pressure After Double Miss CME Group (CME) Q1 Earnings and Revenues Miss Estimates
• Negative Sentiment: Insider sales and large fund trimming — filings show notable insider sales and some institutional reductions, which can amplify near-term downside sentiment even if strategic outlook remains intact. CME GROUP ($CME) Releases Q1 2026 Earnings

Insider Transactions at CME Group

In related news, Director Martin J. Gepsman sold 300 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $305.90, for a total value of $91,770.00. Following the sale, the director directly owned 24,999 shares in the company, valued at approximately $7,647,194.10. The trade was a 1.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Jonathan L. Marcus sold 3,291 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $333.37, for a total value of $1,097,120.67. Following the completion of the sale, the general counsel owned 7,192 shares in the company, valued at $2,397,597.04. This represents a 31.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 8,539 shares of company stock valued at $2,713,821. 0.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CME Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CME. Elkhorn Partners Limited Partnership bought a new stake in CME Group in the 4th quarter valued at about $27,000. Strive Asset Management LLC bought a new stake in shares of CME Group during the third quarter valued at about $32,000. Acumen Wealth Advisors LLC bought a new stake in shares of CME Group during the fourth quarter valued at about $33,000. Kemnay Advisory Services Inc. bought a new stake in shares of CME Group during the fourth quarter valued at about $39,000. Finally, Uniplan Investment Counsel Inc. increased its position in shares of CME Group by 281.6% during the fourth quarter. Uniplan Investment Counsel Inc. now owns 145 shares of the financial services provider’s stock valued at $40,000 after buying an additional 107 shares during the period. 87.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on CME shares. Deutsche Bank Aktiengesellschaft lifted their target price on CME Group from $312.00 to $316.00 and gave the stock a “buy” rating in a research note on Thursday, February 5th. Piper Sandler lifted their target price on CME Group from $313.00 to $329.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 15th. Jefferies Financial Group lowered their target price on CME Group from $356.00 to $349.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Barclays lowered their target price on CME Group from $344.00 to $343.00 and set an “equal weight” rating on the stock in a research note on Monday, April 13th. Finally, TD Cowen lifted their target price on CME Group from $328.00 to $340.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, CME Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $309.94.

About CME Group

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.